featured
Comparison of Duration of Response vs Conventional Response Rates and PFS as Efficacy Endpoints in Simulated Immuno-Oncology Clinical Trials
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Network Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-Oncology Clinical Trials
JAMA Netw Open 2021 May 03;4(5)e218175, C Hu, M Wang, C Wu, H Zhou, C Chen, S DiedeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.